Pharmaceutical company Lupin has received tentative approval from the United States Food and Drug Administration to market its cholesterol lowering Pitavastatin tablets in the American market. has received approval for Pitavastatin tablets in the strength of 1 milligram, 2 mg and 4 mg. Pitavastatin is a generic version of Kowa's Livalo tablets in t
NEW YORK In a story Dec. 30 about global deals, The Associated Press reported erroneously that Dow DuPont's products will include Ziploc bags and Saran Wrap. Dow Chemical developed those products but sold them to S.C. Johnson & Son.
Release date- 28122015- Eisai Co., Ltd. announced today that regarding the acquisition of Chinese generic pharmaceutical company Liaoning TianYi Biological Pharmaceutical Co., Ltd. previously announced on November 27, 2015, the conditions of transfer have been arranged, including receiving a new business license from the regulatory authority in Chi
Eisai Co., Ltd. announced today that regarding the acquisition of Chinese generic pharmaceutical company Liaoning TianYi Biological Pharmaceutical Co., Ltd. previously announced on November 27, 2015, the conditions of transfer have been arranged, including receiving a new business license from the regulatory authority in China, and the acquisition
Teligent, Inc., a New Jersey- based specialty generic pharmaceutical company, today announced it has submitted its fourteenth and fifteenth abbreviated new drug applications to the U.S. Food and Drug Administration of 2015, which brings the Company's total number of ANDA submissions now pending at the FDA to thirty-three. We believe our current p
Torrent Pharmaceutical Ltd has obtained the approval of the US Food and Drug Administration to launch a generic arthritis drug. The company will launch Celacoxib capsules in 50 mg, 100 mg, 200 mg and 400 mg strengths. The drug is the generic version of Celebrex capsules of Pfizer.
The FDA has not yet created a pathway for biosimilar drugs to enter the U.S. market, even though other countries have approved these lifesaving drugs as far back as 2006. ". Leigh Purvis, Director of AARP's Health Services Research, spoke of how consumers will benefit from biosimilars competition. The median income among Medicare beneficiaries is a
Accra, Dec 31, GNA- The Ministry of Health on Tuesday inaugurated a Bioequivalence and Biopharmaceutical Research Centre Steering Committee to support local production of generic medicines for critical public health concerns including Tuberculosis, Malaria and HIV/AIDS. Dr Kwaku Agyeman-Mensah, Minister of Health, inaugurating the committee, said t
In order to keep up with the pace of change in the marketplace, regulatory agencies have been developing updated guidance around the development and approval of biosimilars, but there is still a lack of consistency, particularly between the two leading agencies- the FDA and EMA. Moreover, there are some concerns around biosimilar use, for example w
Teva is the world's largest generic drug manufacturer and a top-20 global pharmaceutical company. The risk remains that Teva's top-selling drug, Copaxone, could face generic competition in the U.S. at any time and by May 2015 in most of Europe. However, this risk has been mitigated by Teva's successful conversion of nearly two-thirds of U.S. pa
The pharmaceutical company Lupin Ltd has received provisional approval from the United States Food and Drug Administration to market its generic version of Prezista tablets indicated for the. The company can market its Darunavir Ethanolate tablets in multiple strengths in the US market for treatment of HIV-1 infections. The sales data for Sep 2014
A pharmaceutical firm that specialises in patented biopharmaceutical, modernised traditional Chinese medicine, branded generics and active pharmaceutical ingredients, Tianyin Pharmaceutical Co, announced that the firm is engaged in discussion with a pharmaceutical industry strategic partner to form an Alliance in building a nationwide mTCM...
IGI Laboratories today announced it executed a license, development, supply and marketing agreement with a large multi-national pharmaceutical company. The agreement designates IGI Laboratories, Inc. as the developer and manufacturer of a generic topical pharmaceutical drug product, which will be licensed, marketed and distributed in the United Sta
IGI Laboratories, Inc., a New Jersey based generic topical pharmaceutical company, today announced it executed a license, development, supply and marketing agreement with a large multi-national pharmaceutical company. The agreement designates IGI Laboratories, Inc. as the developer and manufacturer of a generic topical pharmaceutical drug product,.
The major players include Hospira, Sandoz, Hikma Pharmaceuticals, Fresenius Kabi and Teva Pharmaceutical Industries. To date, only a handful of companies have gained regulatory approval for biosimilars in Europe, and the US is likely to remain elusive to all but a select few. Among these, as the only US-based company with approval for biosimilars i
Aurobindo Pharma has received US Food and Drug Administration's approval for two of its generic drugs, following which the company stocks gained positive traction. Aurobindo Pharma has received US Food and Drug Administration's approval for two of its generic drugs, following which the company stocks gained positive traction. Aurobindo Pharma Ltd i
-Intellipharmaceutics International Inc., a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced that the Company is scheduled to present at the annual Biotech ShowcaseTM conference on January 11, 2017.
CANONSBURG- Mylan is posting a strong gain in afternoon trading on Friday, with shares of the drug maker climbing by 2.5 percent. The gain by Mylan comes after the company announced the launch of a generic version on Johnson& Johnson's Concerta tablets for the treatment of Attention Deficit Hyperactivity Disorder. Mylan also announced the launch of
This week, Lupin received tentative approval for generic Giazo Tablets, Aurobindo Pharma got US FDA approval for 2 drugs and Glenmark Pharma gets USFDA approval for Tretinoin Capsules. Lupin receives tentative approval for generic Giazo Tablets Pharma Major Lupin Limited announced that it has received tentative approval for its Balasalazide Disodiu
The global biosimilars market was valued at $1.8 billion in 2013 and nearly $2.0 billion in 2014. The market is expected to reach nearly $4.0 billion by 2019, with a compound annual growth rate of 15% from 2014 through 2019.. -Detailed analysis of the emerging regulatory framework in regulated markets as well as comparisons of biosimilar guidelines
Reddy s today announced the re-launch of its Esomeprazole Magnesium Delayed-Release Capsules, a therapeutic equivalent generic version of Nexium Delayed-Release capsules in the US market. Nexium is a registered trademark of ASTRAZENECA AB CORPORATION. Reddy s Laboratories Ltd. is an integrated pharmaceutical company, committed to accele
KUALA LUMPUR: THE implementation of the Trans Pacific Partnership pact should pave the way for positive growth for the pharmaceutical industry in Malaysia, said Guardian Malaysia chief executive officer Peter J. Dove. "I will be disappointed if the TPP meant that we could not bring down the prices of generic drugs, as one of the things we are look
The highest price tag came in November, when Pfizer and Allergan announced the biggest pharmaceutical deal in history. Pfizer, the maker of cholesterol fighter Lipitor, impotence treatment Viagra and fibromyalgia drug Lyrica, agreed to buy Allergan in November. It would give Pfizer control of Botox and move the company's headquarters to Ireland, cu
Takeda Pharmaceutical Company Limited today announced the details of the business venture which was disclosed November 30, 2015 in the press release titled, "Teva and Takeda establish unique partnership to meet the wide-ranging needs of patients and growing importance of generic medicines use in Japan". Takeda will split off its off-patented and da
By a News Reporter-Staff News Editor at Biotech Week Teligent, Inc., a New Jersey- based specialty generic pharmaceutical company, announced that it has been selected for addition to the NASDAQ Biotechnology Index . The NASDAQ Biotechnology Index is designed to track the performance of a set of NASDAQ listed securities that are classified as ei